問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital (在職)

Division of Neurology

更新時間：2023-11-03

李宜中Lee, Yi-Chun
  • Principal Investigator
  • Clinical Trial Experience (year) 21 years 9 個月

Recruiting Trial

27Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

李宜中

List

36Cases

2020-02-01 - 2023-12-15

Phase III

A Phase 3 Global, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of ION-682884 in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

  • Condition/Disease

    Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

  • Test Drug

    ION-682884 Injection; Inotersen (ISIS 420915) Injection

Participate Sites
4Sites

Recruiting4Sites

2020-02-01 - 2021-09-15

Phase III

A Phase 3, randomized, double-blind, placebo-controlled study evaluating efficacy and safety of rozanolixizumab in adult patients with generalized myasthenia gravis.

  • Condition/Disease

    generalized myasthenia gravis

  • Test Drug

    Rozanolixizumab

Participate Sites
5Sites

Recruiting5Sites

郭育呈
China Medical University Hospital

Division of Neurology

2020-05-01 - 2021-12-27

Phase III

A randomized, open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in adult patients with generalized myasthenia gravis

  • Condition/Disease

    myasthenia gravis

  • Test Drug

    Rozanolixizumab

Participate Sites
4Sites

Not yet recruiting2Sites

Recruiting1Sites

Study ended1Sites

2021-02-03 - 2024-01-25

Phase III

An open-label extension study to evaluate rozanolixizumab in study participants with generalized myasthenia gravis

  • Condition/Disease

    generalized myasthenia gravis

  • Test Drug

    Rozanolixizumab

Participate Sites
5Sites

Not yet recruiting3Sites

Recruiting1Sites

Study ended1Sites

2016-11-16 - 2020-01-31

Phase III

A multicenter, randomized, double-blind, placebo-controlled, phase 3 study to evaluate the efficacy and safety of SA237 as monotherapy in patients with neuromyelitis optica (NMO) and NMO spectrum disorder (NMOSD).

  • Condition/Disease

    neuromyelitis optica (NMO) and NMO spectrum disorder (NMOSD)

  • Test Drug

    SA237

Participate Sites
3Sites

Terminated2Sites

Study ended1Sites

郭育呈
China Medical University Hospital

Division of Neurology

2021-04-01 - 2026-03-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

1 2 3 4
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB